Cargando…

Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data

Background: With an attempt to understand possible mechanisms behind the severity-dependent development of type 2 diabetes (T2D) comorbidities, this study examines the trends of antidiabetic and cardiovascular diseases (CVD) medication prescriptions in individuals with T2D. Methods: The study is bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Safieddine, Batoul, Trachte, Florian, Sperlich, Stefanie, Epping, Jelena, Lange, Karin, Geyer, Siegfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001865/
https://www.ncbi.nlm.nih.gov/pubmed/36901500
http://dx.doi.org/10.3390/ijerph20054491
_version_ 1784904249398788096
author Safieddine, Batoul
Trachte, Florian
Sperlich, Stefanie
Epping, Jelena
Lange, Karin
Geyer, Siegfried
author_facet Safieddine, Batoul
Trachte, Florian
Sperlich, Stefanie
Epping, Jelena
Lange, Karin
Geyer, Siegfried
author_sort Safieddine, Batoul
collection PubMed
description Background: With an attempt to understand possible mechanisms behind the severity-dependent development of type 2 diabetes (T2D) comorbidities, this study examines the trends of antidiabetic and cardiovascular diseases (CVD) medication prescriptions in individuals with T2D. Methods: The study is based on claims data from a statutory health insurance provider in Lower Saxony, Germany. The period prevalence of antidiabetic and CVD medication prescriptions was examined for the periods 2005–2007, 2010–2012, and 2015–2017 in 240,241, 295,868, and 308,134 individuals with T2D, respectively. (Ordered) logistic regression analyses were applied to examine the effect of time period on the number and prevalence of prescribed medications. Analyses were stratified by gender and three age groups. Results: The number of prescribed medications per person has increased significantly for all examined subgroups. For the two younger age groups, insulin prescriptions decreased but those of non-insulin medications increased, while both increased significantly over time for the age group of 65+ years. Except for glycosides and antiarrhythmic medications, the predicted probabilities for CVD medications increased over the examined periods, with lipid-lowering agents demonstrating the highest increase. Conclusions: Results point towards an increase in medication prescriptions in T2D, which is in line with the evidence of the increase in most comorbidities indicating morbidity expansion. The increase in CVD medication prescriptions, especially lipid-lowering agents, could explain the specific development of severe and less severe T2D comorbidities observed in this population.
format Online
Article
Text
id pubmed-10001865
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100018652023-03-11 Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data Safieddine, Batoul Trachte, Florian Sperlich, Stefanie Epping, Jelena Lange, Karin Geyer, Siegfried Int J Environ Res Public Health Article Background: With an attempt to understand possible mechanisms behind the severity-dependent development of type 2 diabetes (T2D) comorbidities, this study examines the trends of antidiabetic and cardiovascular diseases (CVD) medication prescriptions in individuals with T2D. Methods: The study is based on claims data from a statutory health insurance provider in Lower Saxony, Germany. The period prevalence of antidiabetic and CVD medication prescriptions was examined for the periods 2005–2007, 2010–2012, and 2015–2017 in 240,241, 295,868, and 308,134 individuals with T2D, respectively. (Ordered) logistic regression analyses were applied to examine the effect of time period on the number and prevalence of prescribed medications. Analyses were stratified by gender and three age groups. Results: The number of prescribed medications per person has increased significantly for all examined subgroups. For the two younger age groups, insulin prescriptions decreased but those of non-insulin medications increased, while both increased significantly over time for the age group of 65+ years. Except for glycosides and antiarrhythmic medications, the predicted probabilities for CVD medications increased over the examined periods, with lipid-lowering agents demonstrating the highest increase. Conclusions: Results point towards an increase in medication prescriptions in T2D, which is in line with the evidence of the increase in most comorbidities indicating morbidity expansion. The increase in CVD medication prescriptions, especially lipid-lowering agents, could explain the specific development of severe and less severe T2D comorbidities observed in this population. MDPI 2023-03-03 /pmc/articles/PMC10001865/ /pubmed/36901500 http://dx.doi.org/10.3390/ijerph20054491 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Safieddine, Batoul
Trachte, Florian
Sperlich, Stefanie
Epping, Jelena
Lange, Karin
Geyer, Siegfried
Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data
title Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data
title_full Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data
title_fullStr Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data
title_full_unstemmed Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data
title_short Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017—A German Longitudinal Study Based on Claims Data
title_sort trends of antidiabetic and cardiovascular diseases medication prescriptions in type 2 diabetes between 2005 and 2017—a german longitudinal study based on claims data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001865/
https://www.ncbi.nlm.nih.gov/pubmed/36901500
http://dx.doi.org/10.3390/ijerph20054491
work_keys_str_mv AT safieddinebatoul trendsofantidiabeticandcardiovasculardiseasesmedicationprescriptionsintype2diabetesbetween2005and2017agermanlongitudinalstudybasedonclaimsdata
AT trachteflorian trendsofantidiabeticandcardiovasculardiseasesmedicationprescriptionsintype2diabetesbetween2005and2017agermanlongitudinalstudybasedonclaimsdata
AT sperlichstefanie trendsofantidiabeticandcardiovasculardiseasesmedicationprescriptionsintype2diabetesbetween2005and2017agermanlongitudinalstudybasedonclaimsdata
AT eppingjelena trendsofantidiabeticandcardiovasculardiseasesmedicationprescriptionsintype2diabetesbetween2005and2017agermanlongitudinalstudybasedonclaimsdata
AT langekarin trendsofantidiabeticandcardiovasculardiseasesmedicationprescriptionsintype2diabetesbetween2005and2017agermanlongitudinalstudybasedonclaimsdata
AT geyersiegfried trendsofantidiabeticandcardiovasculardiseasesmedicationprescriptionsintype2diabetesbetween2005and2017agermanlongitudinalstudybasedonclaimsdata